A 62-year-old man was admitted to the general medicine service with a 2-month history of odynophagia, fevers, rigors, a 22-kg unintentional weight loss and watery diarrhea. He had moved to Canada 25 years earlier from Guangzhou, China (Guangdong Province) and had last visited China 1 year before presentation. The patient had been diagnosed with HIV infection 20 years earlier. One year before presentation, his CD4 count and viral load were 24 cells/μL and 144 copies/ml, respectively. He had been treated for Pneumocystis jirovecii pneumonia on 2 occasions, 12 and 20 years previously. He intermittently complied with his antiretroviral therapy (emtricitabine, tenofovir, darunavir, ritonavir and raltegravir) and his opportunistic infection prophylaxis (trimethoprim–sulfamethoxazole for P. jirovecii pneumonia and toxoplasmosis prophylaxis). Other medical comorbidities included hepatitis B coinfection and chronic obstructive pulmonary disease.

On initial examination, the patient appeared thin and cachectic. Examination of the heart and lungs was within normal limits. There was no hepatosplenomegaly or palpable lymphadenopathy. The oropharynx was clear. Skin examination showed red papular lesions scattered on the patient’s face and back. He had daily fever (temperature > 38°C) for the first week of his hospital stay, with a maximum temperature of 38.4°C. At presentation, his absolute CD4 count was 0 cells/μL, and his viral load was 3243 copies/mL. He had severe neutropenia (nadir 0.2 × 10⁹/L) and thrombocytopenia (nadir 32 × 10⁹/L). His liver enzyme levels were mildly elevated (aspartate aminotransferase 88 U/L, alanine aminotransferase 39 U/L and alkaline phosphatase 128 IU/L). His renal function and electrolytes were within normal limits.

On hospital day 5, a filamentous fungus was isolated in 3 peripheral blood culture bottles after 5 days of incubation in an automatic incubator. Subsequent speciation identified Talaromyces marneffei (Figure 1). Stool examination for ova and parasites identified Clonorchis sinensis eggs. Stool culture was negative for Campylobacter, Escherichia coli 0157, Salmonella, Yersinia and Shigella. Multiple sputum samples were negative for acid-fast bacilli. Serologic testing gave negative results for hepatitis C antibody and Strongyloides stercoralis IgG antibody by enzyme-linked immunosorbent assay, and positive results for hepatitis B surface antigen, e antigen and core antibody. Biopsy of a skin lesion showed nonspecific interface dermatitis, with no fungal elements seen on periodic acid–Schiff staining; fungal cultures of the skin lesion were not performed. Gastroscopy showed mild gastritis, and Helicobacter pylori was identified on histopathological examination. Computed tomography of the thorax, abdomen, pelvis and head showed retroperitoneal and mesenteric lymphadenopathy, with no findings suggestive of metastatic fungal disease. Ultrasonography of the abdomen showed mild hepatic steatosis; the gallbladder was normal.

The infectious diseases service was consulted, and treatment of the T. marneffei fungemia was initiated with liposomal amphotericin B induction for 2 weeks, followed by oral itraconazole therapy for 10 weeks. Primary prophylaxis with oral itraconazole therapy should be considered for patients with HIV infection and CD4 counts less than 100 cells/μL who reside in or travel to endemic areas.

**KEY POINTS**

- *Talaromyces marneffei* should be considered in immunocompromised people with a travel history to endemic areas including southeast Asia, northern India and southern China.
- Characteristic presentation features may include several weeks of fevers, weight loss and skin lesions (papules, ulcers or abscesses).
- Diagnosis is made by fungal culture and confirmed through molecular techniques such as the polymerase chain reaction assay; however, diagnosis may be delayed if laboratories are not equipped with these techniques or samples need to be sent to reference laboratories.
- Treatment of *T. marneffei* fungemia is with liposomal amphotericin B induction for 2 weeks, followed by oral itraconazole therapy for 10 weeks.
- Primary prophylaxis with oral itraconazole therapy should be considered for patients with HIV infection and CD4 counts less than 100 cells/μL who reside in or travel to endemic areas.
The patient was seen by the hematology service, who recommended granulocyte colony-stimulating factor for 5 days for his neutropenia. His thrombocytopenia may have been related to HIV-associated idiopathic thrombocytopenia purpura, the trimethoprim–sulfamethoxazole or the *T. marneffei* infection. At 4 months follow-up, he had a platelet count of 232 × 10⁹/L, neutrophil level of 0.5 × 10⁹/L, CD4 count of 7 cells/μL and viral load of 451 copies/mL.

**Discussion**

*Talaromyces marneffei* is a dimorphic fungus endemic to southeast Asia, northern India and southern China (Figure 2). The overt disease incidence increased substantially with the rise of HIV infection in the 1980s, with a decline in incidence since effective antiretroviral therapy became widely instituted in the region.² The main risk factor for *T. marneffei* disease is dysfunctional cell-mediated immunity, commonly secondary to HIV infection, especially in people with a CD4 count less than 100 cells/μL. The incidence has been increasing among patients with immunodeficiency disorders involving the interleukin-12/interferon-γ signalling pathway and among those receiving immunosuppressive T-cell–depleting agents (such as tacrolimus) or monoclonal antibodies (such as rituximab). These patients have higher mortality rates, potentially owing to lack of clinical suspicion.³

The bamboo rat is the only known nonhuman host of *T. marneffei*.⁴ However, there is little evidence of direct rat-to-human transmission. Although the mode of transmission of *T. marneffei* remains unknown, exposure is likely environmental, with inhalation of *T. marneffei* conidia from environments such as soil or plants where bamboo rat feces may be present.⁴

The incubation period for *T. marneffei* is 1–3 weeks in patients with acute disease. In addition, latent *T. marneffei* infection can occur, with disease reactivation at any time in immunocompromised hosts.⁵ Our patient’s illness likely represented reactivation of latent disease in the context of a low CD4 count. He may have acquired the infection during his time of residence in Guangzhou or during one of his return trips, most recently 1 year before presentation at our institution.

**Disseminated Talaromyces marneffei infection**

Clinical features of disseminated *T. marneffei* infection may include fever, lymphadenopathy, weight loss, hepatomegaly, splenomegaly, respiratory and gastrointestinal abnormalities, and skin lesions.²,⁶ The skin lesions are present in 70% of cases and are classically described as necrotic papules, although they may vary in appearance.² Because the other symptoms are nonspecific, the skin lesions may play an important role in prompting consideration of this diagnosis, increasing pretest probability and making the diagnosis through isolation of *T. marneffei* on biopsy.²,⁶ In a retrospective cohort study of patients with HIV/AIDS in southern China, mortality was significantly greater in patients with *T. marneffei* than in those without, with an inhospital mortality rate of 17.5% and 7.6%, respectively.⁷

Common laboratory findings in disseminated *T. marneffei* infection include elevated liver enzyme levels, anemia and thrombocytopenia.²,⁶

**Diagnosis**

Growing *T. marneffei* on culture is the gold standard method of diagnosis, followed by confirmation that involves showing mould to yeast (Figure 1) conversion, at 25°C and 37°C respectively. More recently, molecular techniques such as the polymerase chain reaction assay and enzyme-linked immunosorbent assay, which often must be performed at a reference laboratory, have been used in an effort to expedite the diagnosis.⁸ In our patient, both culture and the polymerase chain reaction assay were performed and yielded concordant positive results.

**Treatment**

Recommended treatment for severe disease with central nervous system involvement includes liposomal amphotericin B, 5 mg/kg for 4–6 weeks, followed by itraconazole, 400 mg/d given orally for 10 weeks, then secondary prophylaxis.⁹ Treatment for moderate and severe disease (multorgan involvement with or without respiratory failure or shock) without central nervous system involvement includes induction with liposomal amphotericin B, 3–5 mg/kg daily for 2 weeks, followed by itraconazole, 400 mg/d given orally for 10 weeks; in the setting of HIV infection, maintenance therapy with itraconazole, 200 mg/d administered orally, should be given for secondary prophylaxis until the CD4

---

**Figure 1:** *Talaromyces marneffei* identified on a potassium hydroxide smear from a blood culture specimen. Yeast hyphae and arthroconidia were seen under light microscopy at 37°C.
count is greater than 100 cells/μL. Mild disease (cutaneous involvement alone) may be treated with itraconazole, 400 mg/d for 8 weeks, followed by secondary prophylaxis. Itraconazole is a cytochrome P450 3A4 inhibitor; thus, prescribers must be cognizant of potential drug interactions.

**Primary prophylaxis**
Primary prophylaxis with itraconazole, 200 mg/d given orally, is indicated for patients with HIV infection and CD4 counts less than 100 cells/μL who reside in or travel to areas endemic for *T. marneffei* in southeast Asia. Other infections in HIV-infected people may warrant primary prophylaxis (Box 1). Despite the risk of talaromycosis in patients without HIV infection who have immunodeficiency disorders or who take immunosuppressive medications, there are no current guidelines recommending primary prevention in these patients.

**Conclusion**
Our patient’s presentation would be considered fairly common in parts of southeast Asia; however, it is uncommon in North America. This case highlights the importance of increasing awareness of *T. marneffei* in immunocompromised hosts given our diverse patient populations, the increasing use of immunosuppressive therapies and growing international travel. Establishing a correct diagnosis in a timely manner is important since effective treatment is available and manifestations and sequelae of the disease can be severe.

---

**Figure 2:** Map showing regions endemic for *Talaromyces marneffei* (orange shading). Adapted from reference 1 with permission from Leading International Fungal Infection (LIFE).
Box 1: Primary prophylaxis of opportunistic infections with antimicrobial therapy in patients with HIV infection

<table>
<thead>
<tr>
<th>Opportunistic infection</th>
<th>CD4 count, cells/μL</th>
<th>Indication</th>
<th>Regions</th>
<th>Recommended prophylaxis (first line)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberculosis (treatment</td>
<td>All counts</td>
<td>Positive tuberculin skin test or interferon-γ release assay result without evidence of active disease or previous treatment for active or latent tuberculosis</td>
<td>All regions</td>
<td>Isoniazid, 300 mg/d orally, + pyridoxine, 25–50 mg/d orally</td>
</tr>
<tr>
<td>Coccidiodomycosis</td>
<td>&lt; 250</td>
<td>New positive result of IgM or IgG Coccidioides spp. serologic testing (monitored annually if residence in endemic area)</td>
<td>Southern California, Arizona; southern Utah, Nevada, New Mexico; western Texas</td>
<td>Fluconazole, 400 mg/d orally</td>
</tr>
<tr>
<td>Pneumocystis jirovecii</td>
<td>&lt; 200</td>
<td>All patients with CD4 count &lt; 200 cells/μL</td>
<td>All regions</td>
<td>Trimethoprim–sulfamethoxazole, 1 tablet single strength orally daily</td>
</tr>
<tr>
<td>Histoplasmosis</td>
<td>≤ 150</td>
<td>• Residence in or travel to hyperendemic area • High-risk activity (exploring caves, occupational exposure to bird or bat droppings) in endemic areas</td>
<td>• French Guiana, some other regions of South America • Mississippi, Ohio, St. Lawrence River valleys; Caribbean, southern Mexico • Some regions of Central America, Africa, Asia</td>
<td>Itraconazole, 200 mg/d orally</td>
</tr>
<tr>
<td>Talaromycosis</td>
<td>&lt; 100</td>
<td>Residence in or travel to endemic area</td>
<td>Northern Thailand, Vietnam, southern China</td>
<td>Itraconazole, 200 mg/d orally</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>&lt; 100</td>
<td>Positive result of IgG Toxoplasma gondii serologic testing</td>
<td>All regions</td>
<td>Trimethoprim–sulfamethoxazole, 1 tablet double strength orally daily</td>
</tr>
<tr>
<td>Mycobacterium avium</td>
<td>&lt; 50</td>
<td>Not receiving fully suppressive antiretroviral therapy after active Mycobacterium avium complex ruled out</td>
<td>All regions</td>
<td>Azithromycin, 1200 mg orally once weekly</td>
</tr>
</tbody>
</table>

References


Competing interests: None declared.
This article has been peer reviewed.
The authors have obtained patient consent.
Affiliations: Department of Medicine (Waters) and Division of Infectious Diseases (Placialفو and Duffuor), Department of Medicine, University of Toronto; Division of Infectious Diseases (Gough), St. Michael’s Hospital, Toronto, Ont.
Contributors: Mara Waters and Alina Beliavsky drafted the manuscript. All of the authors revised the manuscript critically for important intellectual content, approved the final version to be published and agreed to be accountable for all aspects of the work.
Acknowledgements: The authors thank Dr. Manal Tadros, Dr. Larissa Matukas, Dr. Ramzi Fattouh, the St. Michael’s Microbiology Laboratory, Dr. Juliane Kus and the Public Health Ontario laboratory for their contributions to the microbiology testing in this case.
Correspondence to: Mara Waters, mara.waters@mail.utoronto.ca